Status:

RECRUITING

An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM

Lead Sponsor:

Corxel Pharmaceuticals

Conditions:

Obstructive Hypertrophic Cardiomyopathy

Eligibility:

All Genders

18-85 years

Phase:

PHASE3

Brief Summary

This is an open-label extension study of China cohort in the phase 3 study (CY 6031) of aficamten for the treatment of obstructive HCM (oHCM) to collect long-term safety and tolerability data, includi...

Eligibility Criteria

Inclusion

  • Completion of a Cytokinetics trial investigating CK-3773274
  • LVEF ≥55% at the Screening Visit

Exclusion

  • Has participated in another investigational device or drug study or received an investigational device or drug \<1 month (or 5 half-lives for drugs, whichever is longer) prior to screening. Other investigational procedures while participating in this study are not permitted.
  • Since completion of a previous study of aficamten has:Developed new-onset paroxysmal or permanent atrial fibrillation (AF) requiring rhythm restoring treatment (e.g., direct-current cardioversion, ablation procedure, or antiarrhythmic therapy) \<30 days prior to screening. Patient may rescreen for JX01003 after 30 days if heart rate (HR) \<100 bpm and/or rhythm is stable \>30 days.
  • Undergone septal reduction therapy (surgical myectomy or transcatheter alcohol ablation).
  • Had a confirmed LVEF \<40% with an associated dose interruption during participation in a prior study with aficamten.
  • History of appropriate implantable cardioverter defibrillator (ICD) shock within 30 days prior to screening.
  • Has received treatment with mavacamten.

Key Trial Info

Start Date :

November 14 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

March 15 2026

Estimated Enrollment :

44 Patients enrolled

Trial Details

Trial ID

NCT06116968

Start Date

November 14 2023

End Date

March 15 2026

Last Update

March 6 2024

Active Locations (12)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (12 locations)

1

Beijing Anzhen Hospital

Beijing, China

2

Beijing Chao-yang Hospital, Capital Medical University

Beijing, China

3

Fuwai Hospital, CAMS & PUMC

Beijing, China

4

Peking University Third Hospital

Beijing, China